Dover Corporation

DOV
Financial Analysis · Updated May 13, 2026 · Coverage 2026-Q2
Latest Q Revenue
$2.1B
Q1 2026 · +10.1% YoY
TTM ROIC
11.1%
FY2025 · NOPAT / Invested Capital (Total Equity + Net Debt); NOPAT = Operating Income × (1 − 21% tax rate) · WACC ~8.25% · Moat spread +2.85pp

Financial Snapshot


ticker: DOV step: 04 generated: 2026-05-12 source: quick-research

Dover Corporation (DOV) — Financial Snapshot

Income Statement Summary

Metric FY2022 FY2023 FY2024 YoY
Revenue ~$7.86B $7.68B $7.75B +1%
Gross Margin ~37% ~37% ~37% flat
Operating Margin (adj.) ~20% ~20% ~20% flat
Net Income (GAAP) ~$1.1B ~$1.1B ~$2.1B*
Adj. EPS ~$7.42 $7.52 $8.29 +10%

FY2024 GAAP net income elevated by ~$1B gain from $2B sale of Environmental Solutions Group (closed Oct 2024). GAAP EPS from continuing ops was $10.09; adjusted EPS (excluding gain) was $8.29.

FY2026 guidance: Adj. EPS $8.95–$9.15 on revenue growth of 5–7%. Annualized adj. EPS 3-year CAGR was ~5% (FY2022–FY2024); management targets mid-to-high single-digit growth.

Cash Flow & Balance Sheet (FY2024)

Metric Value
Operating Cash Flow ~$1.2B
Free Cash Flow ~$1.0B
FCF Margin ~13%
Cash & Equivalents ~$1.5B (elevated post-ESG sale)
Total Debt ~$3.5B
Net Debt ~$2.0B (net debt, declining)
Completed Buyback $1.04B in FY2024, retiring ~3.9% of shares

Key Ratios (approximate, FY2024)

  • P/E (adj.): ~18–22x | FCF Yield: ~5%
  • EV/EBITDA: ~14–16x | Dividend Yield: ~1.5%
  • Revenue Growth (FY2024): +1% | FCF Margin: ~13%
  • ROIC: ~15–18% | 3-year adj. EPS CAGR: ~5%

Growth Profile

Dover is a serial acquirer and compounder — it acquires niche industrial businesses, improves margins through the Dover Management System (DMS), then grows organically. Revenue growth is typically 2–6% organic + bolt-on acquisitions. FY2023–2024 were below-trend years: post-pandemic inventory destocking hit the Clean Energy & Fueling and Climate & Sustainability segments hard. FY2024 adj. EPS growth of 10% was helped by ESG sale proceeds and buybacks. FY2025 is expected to be a recovery year as destocking cycles in biopharma single-use components and CO2 refrigeration normalize; FY2026 guidance of 5–7% revenue growth implies a more normalized growth rate.

Forward Estimates

  • FY2025: Revenue recovery expected; adj. EPS ~$8.50–$8.80 (transitional year post-ESG)
  • FY2026: Adj. EPS $8.95–$9.15 (management guidance); revenue growth 5–7%; margins recovering toward 21%+
  • Capital allocation: Dividend growth (69+ years), bolt-on M&A (~$500–800M/year), buybacks when valuation attractive; $1.04B completed in FY2024
  • Dividend: $2.16/share annualized (~1.5% yield); S&P 500 Dividend Aristocrat

Deeper Financial Analysis

The fundamental tier adds 9 additional research dimensions for $DOV.

Revenue Breakdown
Segment revenue, geographic mix, product-line contribution margins, and cohort dynamics.
Financial Trends
Quarter-over-quarter momentum, leading indicators, and inflection point analysis.
Balance Sheet
Debt structure, liquidity runway, dilution risk, and working capital dynamics.
Capital Allocation
Buyback cadence, M&A appetite, dividend policy, and reinvestment priorities.
Returns on Capital (ROIC)
Multi-year ROIC vs. WACC, marginal returns on reinvestment, sales-to-invested-capital efficiency, and moat spread.
GET /api/v1/research/DOV/fundamental$1.00 · Bearer token required
Markdown: /stocks/dov/financials/md · → thesis · → memo